largely at the level of transcription. The COX-2 promoter (COX2p) contains many transcription factor binding motifs, suggesting that regulation of COX-2 gene expression could involve complex interactions among diverse transcription factors. Indeed, CREB, NF-B, and C/EBP-␤ are known to be important in COX-2 gene expression (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . A recent study showed that C/EBP-␤ is required for the induction of COX-2 by stimuli in macrophages but not in fibroblasts (15) , suggesting that there are possible functional interactions between C/EBP-␤ and macrophage-specific factors for COX-2 expression.
PU.1 is a member of the Ets transcription factor family whose expression is most abundant in B cells and macrophages (16 -19) . In the development of lymphoid and myeloid cells, PU.1 expression increases during myeloid differentiation of immature progenitor cells but decreases during erythroid differentiation (17, 19, 20) . PU.1 also determines progenitor cell fate by functionally or physically interacting with other transcription factors such as GATA-1 and GATA-2 to suppress their transcriptional activities (21, 22) . In addition, PU.1 inhibits acetylation of transcription factors by protein-protein interactions with CREB-binding protein (CBP)/p300 (23) .
In some cases, PU.1 transcription activity is stimulated by phosphorylation. LPS treatment induces phosphorylation of PU.1 at Ser 148 , possibly by casein kinase II (24) . Recruitment of PIP/IRF-4 to DNA and subsequent transcriptional synergy are dependent upon phosphorylation of PU.1 Ser 148 (25) . Accordingly, substitution of Ser 148 with alanine abolishes transcriptional activity of PU.1 in association with PIP/IRF4 (25) . Recent studies showed that PU.1 is also phosphorylated at Ser 41 and Ser 142 by Ras-phosphoinositide 3-kinase-dependent externally regulated kinase, Akt, and p38 mitogenactivated protein kinase-mediated pathways, respectively (26, 27) .
Possible involvement of Ets family proteins in COX-2 gene expression was reported recently (28) . PEA3, an Ets family protein, is a potent inducer of COX-2 in human breast cancer cell lines (29) . The transcriptional activity of PEA3 requires an intact C/EBP-␤ binding motif in COX-2p (29) . Although these results were from transient transfection of diverse reporter plasmids containing a partial COX-2p sequence, these results highlight a possible involvement of the ETS transcription factor family in COX-2 gene expression.
Here we examine whether PU.1 is a regulatory partner of C/EBP-␤ for COX-2 gene expression in macrophages. We show that PU.1 binds to the COX-2p in vitro as well as in vivo upon LPS treatment, which leads to COX-2 expression. We also provide evidence that C/EBP-␤ is acetylated in response to treatment with LPS, which is augmented further by PU.1. Our results suggest a novel mechanism by which PU.1 increases COX-2 gene expression, at least in part, by augmenting acetylation of C/EBP-␤.
EXPERIMENTAL PROCEDURES
Cell Culture-A murine macrophage cell line RAW264.7 (ATCC, Rockville, MD) was maintained in Dulbecco's modified Eagle's medium (Cellgro) containing 10% fetal bovine serum (Hyclone), penicillin/streptomycin (Invitrogen), and 2 mM glutamine (Sigma).
Plasmids and Transfection-RAW264.7 cells (0.5 ϫ 10 6 cells) were transfected with plasmids by GenePORTER 2 (Gene Therapy Systems, Inc., San Diego), as specified by the manufacturer. Each transfection was normalized with appropriate empty vector plasmids. Transfected cells were incubated for 14 -16 h in a 37°C, CO 2 incubator. For the LPS treatment, the cells were maintained further without serum overnight and subsequently treated with 1 g/ml LPS in phosphate-buffered saline (Sigma) for different time points. To construct FLAG-tagged PU.1 and its mutant, pcDNA3.1(ϩ) was cut with NheI and HindIII (New England Biolabs) and ligated with a linker containing the FLAG sequence. Subsequently, murine PU.1 and PU.1 S148A were amplified by PCR and were inserted downstream of the FLAG sequence in-frame after digestion with appropriate restriction enzymes. The expression of FLAG-tagged PU.1 and its mutant was determined by ␣-PU.1 antibody (Santa Cruz Biotechnology) as well as M2 antibody (Sigma). pCMVmurine PU.1 and PU.1 S148A were described previously (25) . pCMV-E1A12S/13S and -E1A13S were gifts from Dr. E. White (Rutgers University). All plasmids were prepared by an Endo-free Maxiprep kit (Qiagen).
Electrophoretic Mobility Shift Assay-The assay was performed as described previously (30) . Two hairpin-structured oligonucleotides were designed. The complementary sequences underlined were separated by a guanidine and 4 nucleotides of thymidine that are constructed in a loop. The first oligonucleotide (5Ј-TGATACATCCCGTGGTTTTC-CACGGGATGTATCA-3Ј) represents the sequence from Ϫ738 to Ϫ725 of mouse COX-2p, which was named in this study as a distal binding site. The second (5Ј-CCCACTGGATGCGCGTTTTCGCGCATCCAG-TGGG-3Ј) represents the sequence from Ϫ333 to Ϫ318 of mouse COX-2, which was depicted as a proximal binding site.
Immunoprecipitation and Western Blotting-Total cell lysate was prepared using radioimmune precipitation assay buffer (31) . For immunoprecipitation analysis, 1-2 g of appropriate antibodies was added to precleared cell lysate that had been normalized by protein contents and incubated overnight at 4°C. Immune complexes were captured with 30 l of protein A-Sepharose (Zymed Laboratories, Inc.) for 30 min at 4°C and washed five times with radioimmune precipitation assay buffer. Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membrane (Bio-Rad). Specific bands were revealed using enhanced chemoluminescence (ECL plus, Amersham Biosciences). Nuclear extract was prepared after treating cells with hypotonic buffer (30) . The amount of proteins was quantified by the Bradford assay (Bio-Rad) as specified by the manufacturer to ensure equal loading of samples. The antibodies used in this study were: normal rabbit IgG (Santa Cruz Biotechnology), ␣-PU.1 antibody (rabbit polyclonal from Santa Cruz Biotechnology), ␣-C/EBP-␤ and -␦ (rabbit polyclonal from Santa Cruz Biotechnology), ␣-p300 antibody (rabbit polyclonal from Santa Cruz Biotechnology), and ␣-acetyllysine antibody (mouse monoclonal from Upstate Biotechnology), ␣-COX-2 antibody (rabbit polyclonal from Cayman Chemical).
Chromatin Immunoprecipitation (ChIP) Assay-Reagents were obtained from Upstate Biotechnology, and the assay was performed as specified by the manufacturer. PU.1 binding to the COX-2p was analyzed by PCR with two sets of oligonucleotides. The first set of oligonucleotides (5Ј-TAGGAAGATATCCAACACTAT-3Ј and 5Ј-TAGTTCCAT-GAAAGACTTCAA-3Ј) encompassing the distal binding site generated a 408-bp PCR product. The second set of oligonucleotides (5Ј-CTAATTC-CACCAGTACAGATG-3Ј and 5Ј-ACTAGGCGAGACTCAGCGAAC-3Ј) encompassing the proximal binding site produced a 275-bp PCR product. PCR was performed at 94°C for 30 s, 54°C for 30 s, and 68°C for 30 s with 40 cycles of reactions. PCR for the input was performed with 100 ng of genomic DNA.
RESULTS

PU.1 Binds to the Proximal COX-2 Promoter-Sequence
analysis of the COX-2p by the TFSEARCH program (version 1.3, Tokyo University) revealed several potential c-Ets binding sites. Because most key transcription factor binding sites in the COX-2p are localized within proximal 1 kb of the promoter (5-15), we focused on two c-Ets binding sites located between Ϫ725 and Ϫ734 (5Ј-TACATCCGT-3Ј), and Ϫ320 and Ϫ329 (5Ј-ACTGGATGCG-3Ј). The former is described in this study as the distal site and the latter as the proximal site. An NF-B site is about 330 nucleotides downstream from the distal site and about 70 nucleotides upstream from the proximal site (Fig. 1) .
To examine whether PU.1 recognizes these sites in vitro, we performed an electrophoretic mobility shift assay with probes containing the proximal or distal sites (data not shown). 
FIG. 2. PU.1 binds to the COX-2p in vivo.
After treatment with 100 ng/ml LPS for 0 min, 15 min, 30 min, and/or 1 h, RAW264.7 cells were fixed with formaldehyde, and PU.1-bound DNA was isolated after immunoprecipitation with ␣-PU.1 antibody for ChIP analysis. To demonstrate the specificity of immunoprecipitation, each experiment included no antibody and isotypic IgG antibody controls where a primary antibody was not added and isotypic IgG was added instead of PU.1 antibody, respectively. 100 ng of genomic DNA was used as input control for PCR. To ensure fidelity of PCR, some PCR products were analyzed by Southern blotting. A, PU.1 binds to the distal c-Ets binding site. A DNA fragment of the COX-2p bound to PU.1 was amplified by PCR with distal site-specific primers as described under "Experimental Procedures." B, PU.1 accesses the proximal c-Ets binding site. PCR was performed with proximal site-specific primers as described under "Experimental Procedures." RAW264.7 cells were treated with 1 g/ml LPS for various times, and nuclear extracts were prepared and then incubated with probes containing either the distal or proximal c-Ets binding sites. Both probes yielded protein-DNA complexes in the absence of LPS, and LPS treatment yielded little change in the binding pattern. To determine whether these complexes contained PU.1, the 2-h LPS sample with the proximal site probe was incubated with ␣-PU.1 antibody. Indeed, ␣-PU.1 incubation caused a complete supershift of the protein-DNA complex. Therefore, PU.1 binds, at least, to the proximal Ets site in the COX-2p.
A limitation of the electrophoretic mobility shift assay is that it examines DNA binding activity of proteins out of the cellular context and may not represent regulatory binding to the endogenous gene in response to diverse stimuli. To examine whether PU.1 recognized these two putative binding sites of the endogenous COX-2p in a regulatory fashion upon stimulus, we performed a ChIP assay (Fig. 2) . After LPS treatment for indicated time points, RAW264.7 cells were fixed with formaldehyde. Protein-DNA complexes were immunoprecipitated with ␣-PU.1 antibody, and bound DNA fragments were recovered and subjected to semiquantitative PCR with oligonucleotides specific for the distal and proximal PU.1 binding sites (Fig. 2, A and B, respectively). As shown in Fig. 2 , PU.1 binding to the proximal site was detected as early as 15 min, whereas binding of the distal site was observed within 1 h. Therefore, PU.1 is recruited to the COX-2p in response to treatment with endotoxin in a time-dependent manner, and its access to each site is regulated differentially.
To examine whether recruited PU.1 on the COX-2p results from an increased amount of PU.1 after LPS treatment, we measured total PU.1 levels in cytoplasmic and nuclear protein fractions of RAW cells treated with LPS by Western blot analyses against ␣-PU.1 antibodies. As shown in Fig. 3 , the expression level of PU.1 was not affected significantly by LPS treatment, and immunoreactive PU.1 was confined to the nuclear protein fraction, indicating that PU.1 is expressed constitutively in RAW264.7 cells. Taken together, these data show that PU.1 binds to c-Ets binding sites in the COX-2p and that the LPS induction of PU.1 binding to the endogenous COX-2p is not the result of a simple increase in PU.1 expression.
PU.1 Enhances COX-2 Gene Expression-The LPS induction of PU.1 binding to the endogenous COX-2p suggested that PU.1 might regulate COX-2 expression. To test this, RAW264.7 cells were transiently transfected with a PU.1-expression plasmid with or without LPS treatment for 4 h (Fig. 4) . Although LPS induced COX-2 expression, ectopic expression of PU.1 alone was not sufficient to induce COX-2 (Fig. 4A) . However, PU.1 augmented the LPS induction of COX-2 50 -100% as the amount of the PU.1 expression plasmid increased (Fig. 4 , B and C). These data suggest that a modification of PU.1 induced by LPS treatment is functionally more important than an increased amount of PU.1.
To address this possibility, because phosphorylation at PU.1 Ser 148 is known to be crucial for PU.1 transcriptional activity including its association with PIP/IRF-4 (24), we examined whether mutations of Ser 148 would influence COX-2 gene expression (Fig. 5) . RAW64.7 cells were transfected with plasmids expressing either FLAG-tagged wild type PU.1 or the PU.1 S148A mutant and treated with LPS for 4 h. Equivalent expression of these proteins after transfection was assessed by Western blot with M2 antibody (Fig. 5A ). As shown in Fig. 5A , PU.1 S148A did not increase COX-2 expression in the presence of LPS compared with the induction observed with wild type PU.1. In three additional similar experiments that employed 1 and 2) . The cells transfected with the PU.1 expression plasmid were not treated with LPS (lanes 3 and 4) . B, with LPS treatment, ectopic expression of PU.1 increases COX-2 expression. As in A, the cells transfected with the empty vector plasmid were incubated with or without LPS (lanes 1 and 2) . The cells transfected with increasing amounts of the PU.1-expressing plasmid were treated with LPS (lanes 3-5) . C, quantitation of COX-2 expression. COX-2 expression in B was quantitated by laser densitometric analysis.
PU.1-and PU.1 S148A -expressing plasmids, we obtained comparable results (Fig. 5B) . Together, the above results show that PU.1 is involved in COX-2 expression and that phosphorylation of PU.1 upon LPS treatment is likely to be important for its transcriptional activity so to induce COX-2 expression.
C/EBP-␤ Is Acetylated in Response to Treatment with Endotoxin-C/EBP-␤ is required for the induction of COX-2 by stimuli in macrophages (15), suggesting that there are possible functional interactions between C/EBP-␤ and PU.1, resulting in increased COX-2 gene expression in LPS-treated macrophages. C/EBP-␤ physically interacts with CBP/p300 that have histone acetyltransferase activity (31) (32) (33) . Preliminary data showed that inhibition of histone deacetyltransferase activity by sodium butyrate markedly augmented COX-2 expression elicited by LPS (data not shown). These data prompted us to examine whether C/EBP-␤ becomes acetylated in response to treatment with LPS.
RAW264.7 cells were treated with LPS, and total cell lysate was prepared for immunoprecipitation of C/EBP-␤. Immune complexes of C/EBP-␤ captured by protein A were washed extensively and analyzed by SDS-PAGE and Western blotting with ␣-acetyllysine antibody to reveal acetylated products. LPS treatment rapidly increased acetylation of C/EBP-␤ within 15 min (Fig. 6A) . To confirm this observation further, a reciprocal experiment was performed (Fig. 6B) . Acetylated proteins were immunoprecipitated by the ␤-acetyllysine antibody from total cell lysate and then analyzed by Western blot with ␣-C/EBP-␤ antibody to reveal acetylated C/EBP-␤. Consistent with the data shown in Fig. 6A , acetylation of C/EBP-␤ was detected as early as 15 min of LPS stimulation and remained detectable 1 h after stimulation. In these experiments, the total amount of immunoreactive C/EBP-␤ was not significantly affected by LPS treatment, but acetylation of C/EBP-␤ was increased in a timedependent fashion by LPS treatment (Fig. 7) , indicating that acetylation of C/EBP-␤ is not the result of increased expression C/EBP-␤. Taken together, these data show that acetylation of C/EBP-␤ takes place in response to LPS treatment.
PU.1 Increases Acetylation of C/EBP-␤ by Facilitating a Protein-Protein Interaction between C/EBP-␤ and CBP/p300 -Be-
cause PU.1 interacts with CBP/p300 and modulates acetylation of other transcription factors that interact with CBP/p300 (23, 34), we tested whether PU.1 affects acetylation of C/EBP-␤ (Fig. 8) . RAW264.7 cells were transfected with different amounts of a PU.1 expression vector and stimulated with LPS for 1 h, a time point when acetylation of C/EBP-␤ declined close to basal levels (Fig. 6 ). Total cell lysate was immunoprecipitated with ␣-C/EBP-␤ antibody, and immune complexes were analyzed by Western blot with the ␣-acetyllysine antibody to reveal the acetylated form of C/EBP-␤. As shown in Fig. 8A , acetylation of C/EBP-␤ increased in a dose-dependent fashion FIG. 5 . PU.1 serine 148 is crucial for induction of COX-2 expression. A, RAW264.7 cells were transfected with either 6 g of empty vector plasmid pcDNA3.1(ϩ) or 6 g of plasmids encoding FLAGtagged PU.1 or PU.1 S148A in the presence or absence of 1 g/ml LPS for 4 h. COX-2 expression was measured by Western blotting (WB) of total cell lysate. Expressions of FLAG-tagged PU.1 and its Ser 148 mutant were monitored by Western blotting with M2 antibody as shown in the bottom panel. B, in three independent experiments, COX-2 expression in response to transfected PU.1 (wtPU.1) or PU.1 S148A (mPU.1) was quantitated by laser densitometric analysis. with transfected PU.1 expression plasmid, which supports a conclusion that PU.1 increases acetylation of C/EBP-␤.
To examine whether PU.1-dependent acetylation of C/EBP-␤ resulted from increased protein-protein interaction between C/EBP-␤ and CBP/p300, RAW264.7 cells were transfected with 8 g of either an empty vector plasmid or the plasmid encoding PU.1 in the presence and absence of LPS for 1 h (Fig. 8B) . After immunoprecipitation of C/EBP-␤, we performed Western blot analysis with ␣-p300 antibody to reveal CBP/p300 bound to C/EBP-␤. Although PU.1 or LPS alone had little effect, PU.1 with LPS treatment greatly augmented the interaction between the two proteins (Fig. 8B) , indicating that PU.1 plays a role in increasing a physical interactions between C/EBP-␤ and CBP/p300 after LPS treatment. Taken together, these data suggest that PU.1 activated by LPS treatment facilitates the interaction between C/EBP-␤ and CBP/p300, which leads to augmented acetylation of C/EBP-␤.
E1A Inhibits Acetylation of C/EBP-␤ and COX-2 Expression-
The adenovirus E1A protein binds to CBP/p300 and suppresses transcription by either blocking histone acetyltransferase activity or sequestering CBP/p300 (35) (36) (37) . It is also known that E1A inhibits transcriptional activity of C/EBP-␤ by competing for the CH3 domain on CBP/p300 where both E1A and C/EBP-␤ bind (32). Therefore, it was possible that E1A might interfere with acetylation of C/EBP-␤ leading to a decrease in COX-2 gene expression.
To test this possibility, RAW264.7 cells were transfected with plasmids expressing human adenovirus 5 E1A 12S and E1A 13S (38) followed by treatment with LPS for 15 min before preparation of total cell extracts (Fig. 9A) . As shown in Fig. 9A , 1 and 2) or the PU.1 expression vector (lane 3 and 4) in the presence or absence of 1 g/ml LPS for 1 h. Equal amounts of proteins were used for immunoprecipitation of C/EBP-␤. As a positive control, p300 immunoprecipitation was also performed (lane 5). Immune complexes were analyzed by SDS-PAGE and Western blotting with ␣-p300 antibody to reveal that p300 interacts with C/EBP-␤.
E1A suppressed acetylation of C/EBP-␤ induced by LPS treatment. To examine whether E1A down-regulated COX-2 expression, RAW264.7 cells transfected with the E1A 13S-expressing vector were incubated with LPS for 4 h to induce COX-2 protein expression. As shown in Fig. 9 , B and C, E1A suppressed COX-2 gene expression elicited by LPS treatment. Taken together, these results suggest that E1A is able to interfere with acetylation of C/EBP-␤ elicited by LPS treatment, which leads to down-regulation of COX-2 gene expression. DISCUSSION COX-2 is induced by diverse stimuli that are relevant to the pathogenesis of severe sepsis, such as tumor necrosis factor-␣, interleukin-1␤, and LPS, in various cell types including macrophages (1). COX-2 is induced in lung in response to LPS challenge, indicating that COX-2 may be involved in pathogenesis of the acute respiratory distress syndrome (39, 40) . COX-2 expression, in part, results from complex regulatory mechanisms of transcription, which differ depending on stimuli and cell type. In macrophages, COX-2 gene expression is regulated by C/EBP-␤ and its cognate binding site at position Ϫ138/130, whereas CREB and NF-B binding sites seem to have nonessential roles (5, 15) . Macrophages from C/EBP-␤ homozygous null mice are unresponsive to LPS stimulation, but fibroblastic cells respond normally (15) . This result indicates that there are macrophage-specific regulators for COX-2 expression. In transcriptional regulation, macrophages differ from many cell types by the presence of myeloid cell type-specific Ets family protein PU.1 (16) . Sequence analysis revealed the existence of c-Ets binding sites in the COX-2p. Therefore, the present study examined whether PU.1 is involved in COX-2 expression.
Our data show that PU.1 binds to the COX-2p in vivo upon LPS stimulation and that expression of PU.1 in the presence of LPS increases acetylation of C/EBP-␤, which is closely correlated to COX-2 induction. The present results, combined with published data, suggest a possible mechanism by which PU.1 increases COX-2 gene expression (Fig. 10) . LPS treatment induces phosphorylation of PU.1 that subsequently binds to its cognate binding sites in the COX-2p. Recruitment of PU.1 to 1 and 2) or different amounts of the E1A 13S-expressing vector plasmid (lanes 3 and 4) , cells were treated with mock or 1 g/ml LPS for 4 h. 20 g of total cell proteins were loaded for Western blot analysis of COX-2 expression. C, quantitation of COX-2 expression. The expression of COX-2 in B was quantitated by laser densitometry.
the promoter may increase the local concentration of CBP/ p300, providing greater access to C/EBP-␤. Acetylation of this key transcription factor seems to be involved in COX-2 gene expression.
Results of ChIP analyses showed that the proximal binding site is more accessible than the distal site, suggesting that recruitment of PU.1 is regulated differentially. Although this may be caused by differential modification of PU.1 upon stimuli, it is more likely that that PU.1 binding is controlled by the context of a COX-2p. It is noteworthy that the proximal site is located between the NF-B and C/EBP-␤ binding sites, which are involved in the transcriptional regulation of COX-2 gene expression. It is possible that these two factors and transcription coactivators such as CBP/p300 cooperate to open up the proximal PU.1 binding site.
Similar to previously published results (24) , our data show that the level of PU.1 expression is not changed by LPS treatment. Interestingly, ectopic expression of PU.1 failed to induce COX-2 expression. Similarly, the level of C/EBP-␤ is not changed significantly upon LPS treatment, and overexpression of C/EBP-␤ also failed to induce COX-2 gene expression. In a sharp contrast, overexpression of inhibitor B kinase-␤ to activate NF-B fully induced COX-2 gene expression (data not shown). These results might highlight importance of modifications of involved transcription factors upon stimuli. Consistent with this notion, we found that phosphorylation of PU.1 at Ser 148 potentiates COX-2 gene expression. In addition, differential phosphorylation sites of PU.1 were reported in diverse cell types and stimuli (26, 27) . Therefore, it is likely that PU.1 transcriptional activity is controlled by signal-dependent modifications rather than a simple increase of the amount of PU.1.
Our results cannot exclude the possibility that phosphorylation at other sites is also involved because Akt and p38 mitogen-activated protein kinase-mediated pathways phosphorylate PU.1 at Ser 41 and Ser 142 in B cells, respectively. It is not well understood how multiple phosphorylation events affect transcriptional activity of PU.1, but phosphorylation of Ser 148 enables PU.1 to interact with PIP/IRF-4, which synergistically increases transcriptional activity of composite PU.1/PIP/IRF-4 sites (25, 41, 42) . However, this mechanism may not be relevant to COX-2 expression in macrophages because PU.1/IRF-4 composite binding site is not present in the proximal COX-2p, and the expression of IRF-4 in macrophages is controversial (41, (43) (44) (45) . Alternatively, phosphorylation of PU.1 may increase its interaction with CBP/p300, the complex of which may easily bind to the PU.1 site in the COX-2p. CBP/p300 recruited by PU.1 may increase the probability for other transcription factors to serve as a substrate for histone acetyltransferase activity of CBP/p300. Our data support this possibility because PU.1 activated by LPS enhances the interaction between CBP/p300 and C/EBP-␤ and accordingly increases acetylation of C/EBP-␤.
Recent studies also show a close relationship between histone acetylation and gene activation (46 -48) . On the other hand, acetylation of transcription factors results in either activation or repression of transcription depending on the nature of transcription factors and acetylation sites (49, 50) . Our results show that PU.1 with LPS treatment augments acetylation of a key transcription factor C/EBP-␤ and results in increased production of immunoreactive COX-2, suggesting that acetylation of C/EBP-␤ by PU.1 contributes to COX-2 expression. Expression of C/EBP-␤ generates three isoforms: fulllength, liver-enriched activating protein, and liver-enriched inhibitory protein by promiscuous initiation of translation (5) . Because a single band of acetylated C/EBP-␤ was detected in this study, it is possible that acetylation occurs upstream of the second Met residue in the N-terminal region where liver-enriched activating protein starts. The exact location of acetylated lysine residues is under investigation.
Our data show that adenovirus E1A inhibits acetylation of C/EBP-␤ elicited by LPS treatment, which concurrently leads to a decrease in COX-2 expression. E1A can modulate transcription via inhibition of CBP/p300 function either by sequestering CBP/p300 and/or inhibiting histone acetyltransferase activity (35) (36) (37) (38) . Because C/EBP-␤ binds to the same CH3 domain of CBP/p300 where E1A binds (32) , it is likely that E1A suppresses acetylation of C/EBP-␤ by sequestering CBP/p300.
Functional similarities between E1A and PU.1 have been reported in blocking erythroid cell differentiation. The similarity stems from, in part, the fact that E1A and PU.1 share binding motifs on CBP/p300 which play a crucial role in erythroid cell differentiation (21, (51) (52) (53) . A recent study also demonstrated that, like E1A, PU.1 suppresses acetylation of GATA-1 in vivo and other related transcription factors in vitro.
In the present study we show that PU.1 increases acetylation of C/EBP-␤, whereas E1A suppresses acetylation (23) . This difference may be for several reasons. Because a PU.1 binding motif on CBP/p300 is not mapped precisely, it is possible that the PU.1 binding motif does not completely overlap with that of C/EBP-␤ on CBP/p300. Even if the two binding motifs overlap, it is possible that C/EBP-␤ has higher affinity to CBP/p300 than PU.1. Thus, PU.1 may not effectively sequester CBP/p300 from C/EBP-␤. It is also possible that modification of PU.1 in response to stimuli regulates interaction between PU.1 and CBP/p300, which makes their interactions temporary. Finally, it is possible that DNA affects kinetics of interaction between PU.1 and CBP/p300 so that DNA bound PU.1 could have different affinity to CBP/p300. Unlike E1A, PU.1 binding sites are present in other macrophage-specific gene enhancer regions. In the proximal COX-2p, at least two PU.1 binding sites lie near the C/EBP-␤ binding site.
In summary, we show that PU.1 binds to the COX-2p in a stimulus-dependent manner and increases COX-2 expression in macrophages. Moreover, we provide evidence that PU.1 increases acetylation of C/EBP-␤ elicited by LPS treatment. Our results indicate that PU.1 collaborates with C/EBP-␤ in inducing COX-2 upon stimulus challenge.
